Literature DB >> 9533460

Contribution of overproduced chromosomal beta-lactamase and defective outer membrane porins to resistance to extended-spectrum beta-lactam antibiotics in Serratia marcescens.

H Weindorf1, H Schmidt, H H Martin.   

Abstract

Using clinical strains of Serratia marcescens with low and high resistance to extended-spectrum beta-lactam antibiotics, the relative contribution of chromosomal beta-lactamase and defective outer membrane porins to resistance was determined. Low-level resistance was caused by overproduced beta-lactamase alone. High-level resistance was due to beta-lactamase overproduction and defects of porin OmpF or OmpF and OmpC. Overproduction of beta-lactamase in bacteria with both degrees of resistance was eliminated by transformation with cloned ampD+, the gene (from Escherichia coli) for negative modulation of beta-lactamase induction. In transformants of highly resistant bacteria with normally low and inducible beta-lactamase production, the remaining porin defects alone imparted only minimal resistance to extended-spectrum beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533460     DOI: 10.1093/jac/41.2.189

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 2.  Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.

Authors:  Lucía Fernández; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae.

Authors:  Angela Gomez-Simmonds; Stephania Stump; Marla J Giddins; Medini K Annavajhala; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.